Poseida to Prioritize P-BCMA-ALLO1 Over P-BCMA-101; Program Updates for P-PSMA-101 and P-MUC1C-ALLO1; Poseida Q3 2021 Earnings Summary
Here is a brief preview of this blast: On Tuesday, November 9, Poseida Therapeutics released their Q3 2021 financial results (press release) highlighting their strategic shift towards allogeneic CAR-Ts for their BCMA program. Additionally, management provided further updates on their PSMA and MUC1 candidates. Below, Celltelligence provides insights on Poseida’s overarching strategy to prioritize their allogeneic BCMA and PSMA therapies while discussing their MUC1-targeting approach.